Matthew Barcus
Stock Analyst
(2.88)
# 4,648
Out of 4,648 analysts
22
Total ratings
21.74%
Success rate
18.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Buy | $45 → $27 | $5.56 | +385.61% | 4 | Jun 22, 2023 | |
| ZURA Zura Bio | Initiates: Buy | $14 | $4.37 | +220.37% | 1 | Jun 14, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $1.44 | +386.11% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $29.42 | +8.77% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.97 | +7,307.41% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.45 | +160.87% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $12.81 | -37.55% | 1 | Mar 17, 2023 | |
| VINC Vincerx Pharma | Maintains: Buy | $4 → $3 | $0.36 | +737.99% | 3 | Nov 17, 2022 |
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $5.56
Upside: +385.61%
Zura Bio
Jun 14, 2023
Initiates: Buy
Price Target: $14
Current: $4.37
Upside: +220.37%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $29.42
Upside: +8.77%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.97
Upside: +7,307.41%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.45
Upside: +160.87%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $12.81
Upside: -37.55%
Vincerx Pharma
Nov 17, 2022
Maintains: Buy
Price Target: $4 → $3
Current: $0.36
Upside: +737.99%